Ruth Lopert
Ruth Lopert
Dept of Health Policy & Management, George Washington University and LWC Health
Verified email at
Cited by
Cited by
The international decision support initiative reference case for economic evaluation: an aid to thought
T Wilkinson, MJ Sculpher, K Claxton, P Revill, A Briggs, JA Cairns, ...
Value in health 19 (8), 921-928, 2016
Intussusception risk and disease prevention associated with rotavirus vaccines in Australia's National Immunization Program
JB Carlin, KK Macartney, KJ Lee, HE Quinn, J Buttery, R Lopert, J Bines, ...
Clinical Infectious Diseases 57 (10), 1427-1434, 2013
Comparative effectiveness research and evidence‐based health policy: experience from four countries
K Chalkidou, S Tunis, R Lopert, L Rochaix, PT Sawicki, M Nasser, B Xerri
The Milbank Quarterly 87 (2), 339-367, 2009
A randomized controlled trial of piroxicam in the management of acute ankle sprain in Australian Regular Army recruits: the Kapooka Ankle Sprain Study
MA Slatyer, MJ Hensley, R Lopert
The American journal of sports medicine 25 (4), 544-553, 1997
The high price of “free” trade: US trade agreements and access to medicines
R Lopert, D Gleeson
Journal of Law, Medicine & Ethics 41 (1), 199-223, 2013
Disinvestment and value-based purchasing strategies for pharmaceuticals: an international review
B Parkinson, C Sermet, F Clement, S Crausaz, B Godman, S Garner, ...
Pharmacoeconomics 33, 905-924, 2015
Drug-induced delirium: incidence, management and prevention
GL Carter, AH Dawson, R Lopert
Drug safety 15, 291-301, 1996
Toward a definition of pharmaceutical innovation
S Morgan, R Lopert, D Greyson
Open medicine 2 (1), e4, 2008
Biosimilars and the European experience: implications for the United States
F Megerlin, R Lopert, K Taymor, JH Trouvin
Health Affairs 32 (10), 1803-1810, 2013
How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand
D Gleeson, R Lopert, P Reid
Health Policy 112 (3), 227-233, 2013
Differential pricing of drugs: a role for cost-effectiveness analysis?
R Lopert, DL Lang, SR Hill, DA Henry
The Lancet 359 (9323), 2105-2107, 2002
Does medication adherence lower Medicare spending among beneficiaries with diabetes?
B Stuart, A Davidoff, R Lopert, T Shaffer, J Samantha Shoemaker, J Lloyd
Health services research 46 (4), 1180-1199, 2011
Evidence-based decision-making within Australia's pharmaceutical benefits scheme
R Lopert
Commonwealth Fund, 2009
Prices for innovative pharmaceutical products that provide health gain: a comparison between Australia and the United States
EE Roughead, R Lopert, LN Sansom
Value in Health 10 (6), 514-520, 2007
Use of pharmacoeconomics in prescribing research. Part 3: cost‐effectiveness analysis–a technique for decision‐making at the margin
R Lopert, DL Lang, SR Hill
Journal of clinical pharmacy and therapeutics 28 (3), 243-249, 2003
Use of pharmacoeconomics in prescribing research. Part 5: modelling–beyond clinical trials
DL Lang, R Lopert, SR Hill
Journal of clinical pharmacy and therapeutics 28 (5), 433-439, 2003
The trans Pacific partnership agreement, intellectual property and medicines: differential outcomes for developed and developing countries
D Gleeson, J Lexchin, R Lopert, B Kilic
Global Social Policy 18 (1), 7-27, 2018
Applying rapid ‘de-facto’HTA in resource-limited settings: experience from Romania
R Lopert, F Ruiz, K Chalkidou
Health Policy 112 (3), 202-208, 2013
Impact of Medication Adherence on Medicare Expenditure among Beneficiaries with Heart Failure.
R Lopert, JS Shoemaker, B Stuart, A Davidoff
American Journal of Managed Care 18 (9), 556-63, 2012
Implementing health technology assessment in Ghana to support universal health coverage: building relationships that focus on people, policy, and process
S Hollingworth, M Gyansa-Lutterodt, L Dsane-Selby, J Nonvignon, ...
International journal of technology assessment in health care 36 (1), 8-11, 2020
The system can't perform the operation now. Try again later.
Articles 1–20